Merck KGaA (MRK) Given a €106.00 Price Target at Independent Research

Independent Research set a €106.00 ($123.26) price objective on Merck KGaA (FRA:MRK) in a research report report published on Tuesday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.

Several other analysts also recently issued reports on MRK. JPMorgan Chase & Co. reiterated a neutral rating on shares of Merck KGaA in a report on Tuesday, January 15th. Barclays set a €78.00 ($90.70) price target on Merck KGaA and gave the company a sell rating in a report on Tuesday, January 15th. Nord/LB set a €80.00 ($93.02) price target on Merck KGaA and gave the company a sell rating in a report on Thursday, January 24th. Kepler Capital Markets set a €108.00 ($125.58) price target on Merck KGaA and gave the company a buy rating in a report on Thursday, January 24th. Finally, Sanford C. Bernstein set a €105.00 ($122.09) price target on Merck KGaA and gave the company a buy rating in a report on Tuesday, February 5th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of €101.35 ($117.85).

Shares of MRK opened at €91.62 ($106.53) on Tuesday. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Story: Understanding Average Daily Trade Volume

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.